1 Min Read
May 12 (Reuters) - NEWRON PHARMACEUTICALS SPA:
* RECEIVES EUR11.3M MILESTONE PAYMENTS FOR U.S. APPROVAL OF XADAGO (SAFINAMIDE) Source text for Eikon: Further company coverage: (Gdynia Newsroom)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.